These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 11926199)

  • 1. Conformational analysis: a new approach by means of chemometrics.
    Bruni AT; Leite VB; Ferreira MM
    J Comput Chem; 2002 Jan; 23(2):222-36. PubMed ID: 11926199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Electrochemical behaviour of pantoprazole].
    Knoth H
    Pharmazie; 2004 Mar; 59(3):231. PubMed ID: 15074600
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pantoprazole. A new acid pump inhibitor against peptic ulcer and reflux esophagitis].
    Wilson BV; Knudsen T
    Ugeskr Laeger; 1996 Mar; 158(12):1695-7. PubMed ID: 8644421
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacodynamic comparison of pantoprazole enantiomers: inhibition of acid-related lesions and acid secretion in rats and guinea-pigs.
    Cao H; Wang MW; Sun LX; Ikejima T; Hu ZQ; Zhao WH
    J Pharm Pharmacol; 2005 Jul; 57(7):923-7. PubMed ID: 15969954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chiral resolution of pantoprazole sodium and related sulfoxides by complex formation with bovine serum albumin in capillary electrophoresis.
    Eberle D; Hummel RP; Kuhn R
    J Chromatogr A; 1997 Jan; 759(1-2):185-92. PubMed ID: 9050224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Stability of pantoprazole in an extemporaneously compounded oral liquid.
    Dentinger PJ; Swenson CF; Anaizi NH
    Am J Health Syst Pharm; 2002 May; 59(10):953-6. PubMed ID: 12040734
    [No Abstract]   [Full Text] [Related]  

  • 7. In vivo cytochrome P 450 interactions of the newly developed H+/K(+)-ATPase inhibitor pantoprazole (BY 1023/SK&F 96022) compared to other antiulcer drugs.
    Hanauer G; Graf U; Meissner T
    Methods Find Exp Clin Pharmacol; 1991; 13(1):63-7. PubMed ID: 1651432
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study.
    Miner P; Katz PO; Chen Y; Sostek M
    Am J Gastroenterol; 2003 Dec; 98(12):2616-20. PubMed ID: 14687806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of various salts on the stability of lansoprazole, omeprazole, and pantoprazole as determined by high-performance liquid chromatography.
    Ekpe A; Jacobsen T
    Drug Dev Ind Pharm; 1999 Sep; 25(9):1057-65. PubMed ID: 10518247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in binding properties of two proton pump inhibitors on the gastric H+,K+-ATPase in vivo.
    Shin JM; Sachs G
    Biochem Pharmacol; 2004 Dec; 68(11):2117-27. PubMed ID: 15498502
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pantoprazole versus omeprazole: influence on meal-stimulated gastric acid secretion.
    Dammann HG; Burkhardt F
    Eur J Gastroenterol Hepatol; 1999 Nov; 11(11):1277-82. PubMed ID: 10563540
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [2 new proton pump inhibitors. Possibilities of pantoprazole and lansoprazole].
    Leonhardt U; Ritzel U; Ramadori G
    Internist (Berl); 1996 Sep; 37(9):944-9; discussion 949. PubMed ID: 8964694
    [No Abstract]   [Full Text] [Related]  

  • 13. Identification and synthesis of potential impurities of rabeprazole sodium.
    Pingili RR; Jambula MR; Ganta MR; Ghanta MR; Sajja E; Sundaram V; Boluggdu VB
    Pharmazie; 2005 Nov; 60(11):814-8. PubMed ID: 16320941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pantoprazole treatment does not invoke anti-inflammatory properties in vivo.
    Becker TL; Maróstica M; Ribeiro ML; de Mendonça S; Gambero A; Pedrazzoli J
    Int Immunopharmacol; 2004 Aug; 4(8):1051-7. PubMed ID: 15222979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Somatostatin inhibits gastric acid secretion more effectively than pantoprazole in patients with peptic ulcer bleeding: a prospective, randomized, placebo-controlled trial.
    Avgerinos A; Sgouros S; Viazis N; Vlachogiannakos J; Papaxoinis K; Bergele C; Sklavos P; Raptis SA
    Scand J Gastroenterol; 2005 May; 40(5):515-22. PubMed ID: 16036503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrophotometric determination of omeprazole, lansoprazole and pantoprazole in pharmaceutical formulations.
    Wahbi AA; Abdel-Razak O; Gazy AA; Mahgoub H; Moneeb MS
    J Pharm Biomed Anal; 2002 Nov; 30(4):1133-42. PubMed ID: 12408904
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pantoprazole-induced recurrent anaphylactic shock.
    Fardet L; Izzedine H; Ciroldi M; Tiev KP; Cabane J
    Am J Gastroenterol; 2002 Nov; 97(11):2933. PubMed ID: 12425583
    [No Abstract]   [Full Text] [Related]  

  • 18. [Studies on chiral inversion of dextropantoprazole in human].
    Xie ZY; Yang BH; Zhang YF; Zhong DF
    Yao Xue Xue Bao; 2004 May; 39(5):370-3. PubMed ID: 15338882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Physical characterization of pantoprazole sodium hydrates.
    Zupancic V; Ograjsek N; Kotar-Jordan B; Vrecer F
    Int J Pharm; 2005 Mar; 291(1-2):59-68. PubMed ID: 15707732
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
    Giannini E; Romagnoli P; Fasoli A; Chiarbonello B; Malfatti F; Botta F; Risso D; Lantieri PB; Savarino V; Testa R
    Am J Gastroenterol; 2000 Oct; 95(10):2762-7. PubMed ID: 11051345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.